NCTN Trial Portfolios


Note: For full functionality, it is recommended that users download the PDF file and open it with a PDF reader.

Cancer trials ordered by disease area:


- Brain Cancer Trials
- Breast Cancer Trials
- Endocrine/Neuroendocrine Cancer Trials
- Gastrointestinal (GI) Cancer Trials
- Genitourinary (GU) Cancer Trials
- Gynecologic Cancer Trials
- Head and Neck Cancer Trials
- Leukemia Trials
- Lymphoma Trials
- Myeloma Trials
- Sarcoma Trials
- Skin Cancer Trials (mainly Melanoma)
- Thoracic Cancer Trials
- Pediatric and AYA trials
 - Pediatric Brain Cancer Trials
 - Pediatric Hematologic Trials
 - Pediatric Solid Tumor Trials
 - Adolescent and Young Adult (AYA) Trials

NCTN Brain Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:



NCTN Brain Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2
A071401	II	Mutations
A071701	II	Genomically-Guided Treatment Trial in Brain Metastases
		Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent
A072201	II	Glioblastoma
		A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT)
CCTG CE.7	Ш	for 5-15 Brain Metastases
EAF223	II	Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)
NRG-BN003	Ш	Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
		A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard
NRG-BN011	Ш	Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
		Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for
NRG-BN013	Ш	Intact Brain Metastases
		A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field
		Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal
NRG-BN014	Ш	Metastasis (Radiate-LM)
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced
EAY191-E5	II	Solid Tumors: A ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib,
		a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A
EAY191-N5	II	ComboMATCH Treatment Trial

NCTN Breast Cancer Trials Portfolio (Open as of 11/15/2025)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Adjuvant Post-Neoadjuvant Neoadjuvant Metastatic **S2212** A012103 **EAY191 CCTG MA.39** (SCARLET) HR+/HER2-(ComboMATCH) (OptimICE-PCR) **TNBC** Low risk; Node positive T2-4/N0/M0, or T1-3/N1-Early-Stage, pCR post pre-op 2/M0 chemo + pembrolizumab NRG-BR007 (DEBRA) **Sub-study: EAY191-E5** HR+/HER2-**S2206** (KRAS G12C mutation) A012303 pT1(<=2cm) pN0M0 HR+/HER2-(ShortStop-HER2) Stage II or III HER2+ Early-Stage, pCR post pre-op NRG-BR009 (OFSET) chemo + HER2 blockade HR+/HER2pT1-3/N0-1/M0, Oncotype **Recurrence Score ≤ 25, Premenopausal patients** A012301 (LoTam) HR+/HER2-Early-stage, Low molecular risk, Resected tumor ≤3cm and N0, Postmenopausal pts

Legend by Subtype Status

Green = TNBC

Orange = HER2+ (Any HR status)


Purple = HR+ and HER2-

Pink = Crossdisease trial

NCTN Breast Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint
A012103	Ш	Inhibitor Therapy
A012301	Ш	LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
		ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After
A012303	Ш	Neoadjuvant Chemotherapy with HER2 Blockade
CCTG MA.39	Ш	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
		A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative,
NRG-BR007	Ш	Oncotype Recurrence Score = 18 Breast Cancer (DEBRA)</td
		A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in
NRG-BR009	Ш	Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)</td
		Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint
S2206	Ш	Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
		Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A
S2212	Ш	Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment
EAY191-E5	II	Trial


NCTN Endocrine/Neuroendocrine Cancer Trials Portfolio (Open as of 11/15/2025)



NCTN Endocrine/Neuroendocrine Cancer Trials (Open as of 11/15/2025)


Protocol Number	Phase	Protocol Title
		Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor
A021901	II	Positive Bronchial Neuroendocrine Tumors
		A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab
		(REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical
A092204	II	Cancer
		NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in
CCTG-NE1	II	Metastatic/Unresectable Midgut NET
		Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab
		(NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine
S2012	11/111	Carcinomas (NEC)
		Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus
S2104	II	Observation in High-Risk Pancreatic Neuroendocrine Tumors

NCTN Gastrointestinal Cancer Trials Portfolio (Open as of 11/15/2025)




NCTN Gastrointestinal Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.




Cross-disease trials:



NCTN Gastrointestinal Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
A021806	III	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
		A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic
A022101	Ш	Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
		Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of
A022102	Ш	Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
		Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic
A022106	11/111	Pancreatic Ductal Adenocarcinoma (PLATINUM)
		The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus
CCTG-CO32	Ш	ChemoRadioTherapy for Early Rectal Cancer
		NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable
CCTG-NE1	П	Midgut NET
		A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and
EA2174	11/111	Gastroesophageal Junction Adenocarcinoma
		APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in
EA2192	II	Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
		A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable
EA2222	Ш	Colorectal Liver Metastases: The PUMP Trial
		A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in
EA2234	11/111	Gastric Carcinomatosis - STOPGAP II
NRG-GI003	Ш	A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
NRG-GI006	Ш	Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT)
NRG-GI008	11/111	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
		A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients
NRG-GI011	Ш	(LAP100)
		Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with
NRG-GI012	Ш	Macrovascular Invasion (HELIO-RT)
		Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel
S1922	H	Adenocarcinoma
		Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in
S2012	11/111	Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
		Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-
S2104	II	Risk Pancreatic Neuroendocrine Tumors
		Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in
S2303	11/111	Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A
EAY191-E5	II	ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor,
EAY191-N5	П	in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial


NCTN Genitourinary Cancer Trials Portfolio (Open as of 11/15/2025)



NCTN Genitourinary Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:




NCTN Genitourinary Cancer Trials (Open as of 11/15/2025)


Protocol Number	Phase	Protocol Title
		A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer
		with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene
A031701	П	Alterations
A031702	П	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
		A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell
A031801	П	Carcinoma with Bone Metastasis (RadiCal)
A032102	II	PREcision Diagnostics in Prostate Cancer Treatment (PREDICT)
		MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant Therapy in URothelial
A032103	Ш	CaNcer
A032201	Ш	Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
A032302	Ш	Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
		GAIN-BCG: Gemcitabine Alternating with INtravesical BCG Randomized Against BCG Alone for Patients with Recurrent
A032303	III	High Grade Non-Muscle Invasive Bladder Cancer
		Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-
		Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Brachytherapy Boost
CCTG-PR24	III	in Patients with Unfavorable Risk Localized Prostate Cancer (ASCENDE-SBRT)
CCTC PD3C		A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in
CCTG-PR26	III	Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
EA8134	III	InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Phase III Study of Local or Systemic Therapy INtensification Directed by PET in Prostate Cancer Patients with Post-
EA8191	III	ProstaTEctomy Biochemical Recurrence (INDICATE)
EA0131	111	A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial
EA8192	11/111	Cancer Prior to Nephroureterectomy
LA0132	11/111	A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in
EA8231	III	Anti-PD(L)1-Resistant Advanced Urothelial Cancer
LAGESI		Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients
NRG-GU008	Ш	with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*)
		Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-
NRG-GU010	Ш	Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
		A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or Without
NRG-GU011	П	ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
		Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma
NRG-GU012	П	(RCC) Receiving Immunotherapy (SAMURAI)
NRG-GU013	Ш	The Phase III `High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
		Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-
NRG-GU014	П	Grade T1 Bladder Cancer (PARRC Trial)
NRG-GU015	Ш	The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)
		Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive
S1802	III	Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
		Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for
S1931	III	Metastatic Renal Cell Carcinoma (PROBE Trial)
		A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care
54007	 	(Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1
S1937	III	Therapy
52012	11 /111	Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in
S2012	11/111	Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
52200		A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients
S2200	II	with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
C2210	I.,	A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2
S2210	II	Mutations A Phase III Study of Cabazitaval with or Without Carbonlatin in Patients with Metastatic Castrate Prostate
52212	III	A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate
S2312	111	Cancer (mCRPC), Stratified by Aggressive Variant Signature Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response
S2427	II	to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
52427 EAY191		Molecular Analysis for Combination Therapy Choice (ComboMATCH)
FWITAT	Julei	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A
EAY191-E5	П	ComboMATCH Treatment Trial
	+	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor,
EAY191-N5	П	in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
EAT191-N5	III	III Patients with HEKZ+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

NCTN Gynecologic Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.




Cross-disease trials:



NCTN Gynecologic Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for
AGCT1531	Ш	Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
		A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate
AGCT1532	Ш	and Poor-Risk Germ Cell Tumors
		A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent
EAY191-N4	П	RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
		Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II
NRG-GY024	H	Treatment Trial
		A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients
NRG-GY025	П	with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
		A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-
		oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive,
NRG-GY026	11/111	Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
		A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in
NRG-GY031	I	Recurrent Ovarian and Endometrial Cancer
		A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage
NRG-GY032	II	Endometrial Cancer (RAINBO BLUE & TAPER)
		A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with
		BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First
NRG-GY036	Ш	Line Platinum-Based Chemotherapy
		A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and
		Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally
NRG-GY037	Ш	Advanced Cervical Cancer
		Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in
S2012	11/111	Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors:
EAY191-E5	II	A ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6
EAY191-N5	п	Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

NCTN Head and Neck Cancer Trials Portfolio (Open as of 11/15/2025)



NCTN Head and Neck Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

Sub-study: EAY191-E5 (KRAS G12C mutation)

EAY191
(ComboMATCH)


Sub-study: EAY191-N5 (HER2 amplified)

NCTN Head and Neck Cancer Trials (Open as of 11/15/2025)


Protocol Number	Phase	Protocol Title
		Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced
A092105	П	Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
		Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and
A092205	Ш	Neck Squamous Cell Carcinoma with Platinum Refractory Disease
		SPECT-CT Guided Elective Contralateral Neck Treatment [SELECT] for Patients with Lateralized Oropharyngeal
CCTG-HN11	Ш	Cancer: A Phase III Randomized Controlled Trial
		Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell
EA3132	H	Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
		A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced,
EA3161	11/111	Intermediate Risk HPV Positive OPCA
		A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second
EA3191	H	Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
		Phase III Randomized Trial of Immunotherapy with or Without Consolidative Radiotherapy for Oligometastatic
EA3211	Ш	Head and Neck Squamous Cell Carcinoma
		A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid
EA3231	Ш	Cancer with BRAF V600Em
		Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral
NRG-HN006	11/111	Cavity Cancer
		Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus
		Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell
NRG-HN009	11/111	Carcinoma of the Head and Neck (SCCHN)
		A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for
NRG-HN010	II	Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
		A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance
		Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-
NRG-HN011	II	Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
		Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus
RTOG-1216	11/111	Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
		Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of
		Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or
S2101	II	HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A
EAY191-E5	II	ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6
EAY191-N5	II	Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

NCTN Leukemia Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.




MyeloMATCH and its sub-trials:



NCTN Leukemia Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22
		Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed
A041501	Ш	Precursor B-Cell ALL
		A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-
		Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory
A041703	II	Disease
		A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or
EA9181	Ш	Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
		A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal
EA9213	II	Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
		MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI
MYELOMATCH	Other	MyeloMATCH Clinical Trials
		A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-
MM1MDS-A01	II	Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study
		A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit
MM1OA-EA02	II	Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
		A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib
MM1OA-S03	lii	for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
IVIIVITOA-303	"	A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly
		Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical
MM1YA-CTG01	lii	Trial
WIWITTA-CIGOT	"	Illai
		A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine)
		Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and
		Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse)
MM1YA-S01	П	Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
		A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-
S1905	П	Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
		Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy
		with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic
S1925	Ш	Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study


NCTN Lymphoma Trials Portfolio (Open as of 11/15/2025)



NCTN Lymphoma Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by
A051901	ı	Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
		A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated
A051902	П	CD30 Negative Peripheral T-Cell Lymphomas
		A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront
A052101	Ш	Treatment in Older Patients with Mantle Cell Lymphoma
		A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology
AHOD2131	Ш	Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
		A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or
		Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC
EA4231	П	and BCL2 Rearrangements (HGBCL-DH-BCL2)
		A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with
		Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy
EA4232	Ш	(PTCL-STAT)
		A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual
EA9213	П	Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
		A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-
S1905	II	Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
		A Phace II/III Pandamized Study of P. MiniCHOD with or Without CC 496 (Oral Azacitidina) in Participants Ago
		A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age
S1918	11/111	75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma,
21319	11/111	Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy
S1925	Ш	with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic
31925	1111	Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated
C200F	l.,	,
S2005	II	Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
C2444	l.,	A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For
S2114	II	Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
C2207		Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in
S2207	II	Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma
S2308	Ш	Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
32300	1111	namuomizeu riiase iii stuuy oi iviosunetuzumau vs. nituximau ioi tow Tumor Buruen Follicular Lymphoma

NCTN Myeloma Trials Portfolio (Open as of 11/15/2025)




NCTN Myeloma Trials (Open as of 11/15/2025)


Protocol Number	Phase	Protocol Title
		A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in
		Combination with Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin
A062101	1/11	(GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
		Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel
A062102	II	CAR-T in Multiple Myeloma Patients
		Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-
EAA173	Ш	SMM)
		Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for
EAA181	Ш	Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
		A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus
		Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma with Light
EAA241	H	Chain Cast Nephropathy (LCCN)
		A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered
		Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed
S2209	Ш	by Double or Single-Agent Maintenance
		A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone
		(Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and
S2213	Ш	Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

NCTN Sarcoma Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:




NCTN Sarcoma Trials (Open as of 11/15/2025)


Protocol Number	Phase	Protocol Title
		Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination with
		Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients
AEWS2431	11/111	with Newly Diagnosed Metastatic Ewing Sarcoma
		A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of
AOST2031	Ш	Pulmonary Metastases in Patients with Osteosarcoma
		A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in
AOST2032	11/111	Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
		A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus
EA7211	Ш	Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
		A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for
		the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly
EA7222	Ш	Differentiated Sarcomas
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in
EAY191-E5	II	Advanced Solid Tumors: A ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with
		Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid
EAY191-N5	II	Tumors: A ComboMATCH Treatment Trial

NCTN Skin Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.




Cross-disease trials:



NCTN Skin Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with
A091903	II	Resected Mucosal Melanoma
		Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus
EA6141	11/111	Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
		Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus
NRG-HN014	Ш	Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
		Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II
		Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO
S2101	II	Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid
EAY191-E5	II	Tumors: A ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a
		CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH
EAY191-N5	II	Treatment Trial

NCTN Thoracic Cancer Trials Portfolio (Open as of 11/15/2025)



NCTN Thoracic Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

Sub-study: EAY191-E5 (KRAS G12C mutation)


EAY191
(ComboMATCH)

Sub-study: EAY191-N5 (HER2 amplified)

NCTN Thoracic Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive
A021901	П	Bronchial Neuroendocrine Tumors
A081801	Ш	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
		A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-
A082002	11/111	Negative, Advanced Non-Small Cell Lung Cancer
A082101	П	Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid Mesothelioma
		Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for
A092001	П	Peritoneal Mesothelioma
		Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Participants with Metastatic Non-Small-
CCTG-BR38	Ш	Cell Lung Cancer A Randomized Phase 3 Trial
CTIU2317-		Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer -
A082304-S2402	Ш	PROSPECT LUNG
EA5162	П	Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
		Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291
		(Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer
EA5182	Ш	(NSCLC)
		A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult
EA5221	Ш	with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
		A Randomized Phase III Trial of Checkpoint Blockade in Lung CancEr Patients in the Adjuvant Setting Based on
EA5231	Ш	Pathologic Response Following Neoadjuvant Therapy (CLEAR)
		A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small
LUNGMAP	Other	Cell Lung Cancer (Lung-MAP Screening Study)
NRG-LU007	11/111	RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
		Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by
NRG-LU008	Ш	Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
		A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for
		Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent
S1800E	11/111	Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
		A Randomized Phase III Trial of MRI Surveillance with or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell
S1827	Ш	Lung Cancer
		A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in
		Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-
S1900G	П	Study)
		A Phase II Study of Amivantamab SC (Subcutaneous) in Participants with MET Amplification-Positive Stage IV or
S1900J	П	Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
		A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping
S1900K	II	Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
		A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC
S1933	П	Patients with Borderline Performance Status
		PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance
S2409	II	Durvalumab with or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
		A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non
S2414	Ш	Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A
EAY191-E5	II	ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6
EAY191-N5	П	Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial


NCTN Pediatric Brain and Central Nervous System Tumor Trials (Open as of 11/15/2025)



NCTN Pediatric Brain and Central Nervous System Tumor Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse
ACNS1821	1/11	Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
		A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC#
		748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated with
ACNS1833	Ш	BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
		A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal
		Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell
ACNS2021	П	Tumor
		A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with
		Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk
ACNS2031	Ш	Features
		A Phase II Trial Evaluating Chemotherapy Followed by Response-Based Reduced Radiation Therapy for
ACNS2321	П	Patients with Central Nervous System Germinomas


NCTN Pediatric Hematologic Cancer Trials (Open as of 11/15/2025)



NCTN Pediatric Hematologic Cancer Trials (Open as of 11/15/2025)

Protocol		
Number	Phase	Protocol Title
		A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or
AALL1621	П	Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
		A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed
		High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia,
AALL1732	Ш	and Disseminated B-LLy
		A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a
AALL1821	П	Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
		A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory
AALL2121	П	KMT2A-Rearranged Infant Leukemia
		An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients
		with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell
AALL2131	Ш	Acute Lymphoblastic Leukemia
		A Phone 2 Study of Plinature and in Combination with Chamatharany for Infants with Newly Diagraced Acute
	l	A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute
AALL2321	11	Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
		A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including
	l	Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for
AAML1831	Ш	Patients with FLT3 Mutations
	l	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology
AHOD2131	III	Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
ANHL2121	II	Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

NCTN Pediatric Solid Tumor (other than Brain/CNS) Trials (Open as of 11/15/2025)




NCTN Pediatric Solid Tumor (other than Brain/CNS) Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination with
		Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients with
AEWS2431	11/111	Newly Diagnosed Metastatic Ewing Sarcoma
		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.
AGCT1531	Ш	Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
		A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients
AGCT1532	Ш	with Intermediate and Poor-Risk Metastatic Germ Cell Tumors
		A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added
ANBL1531	Ш	to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
		A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with
ANBL2131	Ш	Newly Diagnosed High-Risk Neuroblastoma
		A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of
AOST2031	Ш	Pulmonary Metastases in Patients with Osteosarcoma
		A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in
AOST2032	11/111	Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
		A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in
ARAR2221	П	Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
ARAR2331	Ш	Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
		Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed
AREN1921	П	Favorable Histology Wilms Tumors (FHWT)
AREN2231	Ш	Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
ARET2121	II	Intravitreal Melphalan for Intraocular Retinoblastoma
		A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk
ARST2032	Ш	Fusion Negative Rhabdomyosarcoma

NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Updated on 11/15/2025)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.



NCTN Adolescent and Young Adult (AYA) Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to
A041501	III	Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
		A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib
A092204	II	Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
		A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-
AALL1821	II	ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
		Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination with Vincristine-Doxorubicin-Cyclophosphamide (VDC)
AEWS2431	11/111	and Ifosfamide-Etoposide (IE) in Patients with Newly Diagnosed Metastatic Ewing Sarcoma
		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and
AGCT1531	Ш	Adult Patients with Germ Cell Tumors
		A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell
AGCT1532	Ш	Tumors
		A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and
AHOD2131	Ш	Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
		A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with
AOST2031	Ш	Osteosarcoma
		A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy
AOST2032	11/111	for Newly Diagnosed Osteosarcoma
		A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell
EA9213	II	Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
		A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in
NRG-BR009	III	Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)</td
		A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic
S1905	1/11	Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)